452 related articles for article (PubMed ID: 26809712)
1. A Fluorescent Oligothiophene-Bis-Triazine ligand interacts with PrP fibrils and detects SDS-resistant oligomers in human prion diseases.
Imberdis T; Ayrolles-Torro A; Duarte Rodrigues A; Torrent J; Alvarez-Martinez MT; Kovacs GG; Verdier JM; Robitzer M; Perrier V
Mol Neurodegener; 2016 Jan; 11():11. PubMed ID: 26809712
[TBL] [Abstract][Full Text] [Related]
2. Development of oligomeric prion-protein aggregates in a mouse model of prion disease.
Sasaki K; Minaki H; Iwaki T
J Pathol; 2009 Sep; 219(1):123-30. PubMed ID: 19479969
[TBL] [Abstract][Full Text] [Related]
3. Low doses of bioherbicide favour prion aggregation and propagation in vivo.
Lafon PA; Imberdis T; Wang Y; Torrent J; Robitzer M; Huetter E; Alvarez-Martinez MT; Chevallier N; Givalois L; Desrumaux C; Liu J; Perrier V
Sci Rep; 2018 May; 8(1):8023. PubMed ID: 29795181
[TBL] [Abstract][Full Text] [Related]
4. Thienyl pyrimidine derivatives with PrP(Sc) oligomer-inducing activity are a promising tool to study prions.
Imberdis T; Ayrolles-Torro A; Verdier JM; Perrier V
Curr Top Med Chem; 2013; 13(19):2477-83. PubMed ID: 24059332
[TBL] [Abstract][Full Text] [Related]
5. Oligomeric-induced activity by thienyl pyrimidine compounds traps prion infectivity.
Ayrolles-Torro A; Imberdis T; Torrent J; Toupet K; Baskakov IV; Poncet-Montange G; Grégoire C; Roquet-Baneres F; Lehmann S; Rognan D; Pugnière M; Verdier JM; Perrier V
J Neurosci; 2011 Oct; 31(42):14882-92. PubMed ID: 22016521
[TBL] [Abstract][Full Text] [Related]
6. Prion protein oligomers in Creutzfeldt-Jakob disease detected by gel-filtration centrifuge columns.
Minaki H; Sasaki K; Honda H; Iwaki T
Neuropathology; 2009 Oct; 29(5):536-42. PubMed ID: 19389076
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic mutations within the hydrophobic domain of the prion protein lead to the formation of protease-sensitive prion species with increased lethality.
Coleman BM; Harrison CF; Guo B; Masters CL; Barnham KJ; Lawson VA; Hill AF
J Virol; 2014 Mar; 88(5):2690-703. PubMed ID: 24352465
[TBL] [Abstract][Full Text] [Related]
8. Infectivity-associated PrP(Sc) and disease duration-associated PrP(Sc) of mouse BSE prions.
Miyazawa K; Okada H; Masujin K; Iwamaru Y; Yokoyama T
Prion; 2015; 9(5):394-403. PubMed ID: 26555211
[TBL] [Abstract][Full Text] [Related]
9. Isolation of soluble and insoluble PrP oligomers in the normal human brain.
Xiao X; Yuan J; Zou WQ
J Vis Exp; 2012 Oct; (68):. PubMed ID: 23070047
[TBL] [Abstract][Full Text] [Related]
10. [Establishment of an assay for PrP(Sc) detection based on streptomycin precipitation].
Dong CF; Huang YX; An R; Chen JM; Wang XF; Shan B; Lei YJ; Han L; Zhang BY; Han J; Dong XP
Bing Du Xue Bao; 2008 May; 24(3):185-9. PubMed ID: 18683554
[TBL] [Abstract][Full Text] [Related]
11. Uptake and degradation of protease-sensitive and -resistant forms of abnormal human prion protein aggregates by human astrocytes.
Choi YP; Head MW; Ironside JW; Priola SA
Am J Pathol; 2014 Dec; 184(12):3299-307. PubMed ID: 25280631
[TBL] [Abstract][Full Text] [Related]
12. Establishment of a simple cell-based ELISA for the direct detection of abnormal isoform of prion protein from prion-infected cells without cell lysis and proteinase K treatment.
Shan Z; Yamasaki T; Suzuki A; Hasebe R; Horiuchi M
Prion; 2016 Jul; 10(4):305-18. PubMed ID: 27565564
[TBL] [Abstract][Full Text] [Related]
13. The paraffin-embedded tissue blot detects PrP(Sc) early in the incubation time in prion diseases.
Schulz-Schaeffer WJ; Tschöke S; Kranefuss N; Dröse W; Hause-Reitner D; Giese A; Groschup MH; Kretzschmar HA
Am J Pathol; 2000 Jan; 156(1):51-6. PubMed ID: 10623653
[TBL] [Abstract][Full Text] [Related]
14. Biochemical Characterization of Prions.
Fiorini M; Bongianni M; Monaco S; Zanusso G
Prog Mol Biol Transl Sci; 2017; 150():389-407. PubMed ID: 28838671
[TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of the anti-prionic activity of newly synthesized congo red derivatives.
Poli G; Ponti W; Carcassola G; Ceciliani F; Colombo L; Dall'Ara P; Gervasoni M; Giannino ML; Martino PA; Pollera C; Villa S; Salmona M
Arzneimittelforschung; 2003; 53(12):875-88. PubMed ID: 14750496
[TBL] [Abstract][Full Text] [Related]
16. Analyses of protease resistance and aggregation state of abnormal prion protein across the spectrum of human prions.
Saverioni D; Notari S; Capellari S; Poggiolini I; Giese A; Kretzschmar HA; Parchi P
J Biol Chem; 2013 Sep; 288(39):27972-85. PubMed ID: 23897825
[TBL] [Abstract][Full Text] [Related]
17. Prion Infectivity Plateaus and Conversion to Symptomatic Disease Originate from Falling Precursor Levels and Increased Levels of Oligomeric PrPSc Species.
Mays CE; van der Merwe J; Kim C; Haldiman T; McKenzie D; Safar JG; Westaway D
J Virol; 2015 Dec; 89(24):12418-26. PubMed ID: 26423957
[TBL] [Abstract][Full Text] [Related]
18. Generation of genuine prion infectivity by serial PMCA.
Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
Vet Microbiol; 2007 Aug; 123(4):346-57. PubMed ID: 17493773
[TBL] [Abstract][Full Text] [Related]
19. Follicular dendritic cell of the knock-in mouse provides a new bioassay for human prions.
Kitamoto T; Mohri S; Ironside JW; Miyoshi I; Tanaka T; Kitamoto N; Itohara S; Kasai N; Katsuki M; Higuchi J; Muramoto T; Shin RW
Biochem Biophys Res Commun; 2002 Jun; 294(2):280-6. PubMed ID: 12051707
[TBL] [Abstract][Full Text] [Related]
20. Generation of antisera to purified prions in lipid rafts.
Hnasko R; Serban AV; Carlson G; Prusiner SB; Stanker LH
Prion; 2010; 4(2):94-104. PubMed ID: 20647769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
